The orthopedic device maker will limit operations beginning April 13. Its production lines for critical device components will remain operational.
This is one of several measures Zimmer is implementing to offset financial losses stemming from elective procedure bans across the country. Anticipating a roughly 10 percent drop in first-quarter revenues, Zimmer announced CEO Bryan Hanson is temporarily eliminating his salary, while other leaders are having their compensation reduced.
More articles on devices:
Dr. Daniel Yoshor excited by new challenge at Penn Medicine
New York neurosurgeon recovers from COVID-19, volunteers at hospital ICU
Neurosurgeon, dentist’s 3D printed masks evolved production, being made worldwide: 5 details
